CC vs HON: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HON is the larger of the two ($68.85B market cap): the incumbent the market prices for continued execution (21.97x forward earnings, beta 0.88). CC is the smaller challenger ($1.69B), cheaper on forward earnings (6.53x): more room to run, but more to prove. If you believe HON earns its premium (21.97x forward earnings, so the market expects more from it), HON fits. If you believe in paying less for profit, CC fits at 6.53x.

CC vs HON: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCCHONWhat it tells you
Market cap$1.69B$68.85BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E6.5321.97Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.470.88Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range4% of range32% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.933.07How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: CC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CC and HON affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CC and HON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CC and HON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does The Chemours Company (CC) do?

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Trailing twelve-month revenue is roughly $5.84 billion, about the same as full-year 2025, and the company operates globally across industrial, construction, automotive, and electronics end markets with about 5,700 employees.

Full CC guide

What does Honeywell International (HON) do?

Honeywell, which now operates as Honeywell Technologies (Nasdaq: HON), describes itself as a global, pure-play automation company serving the building, industrial and process sectors through services, solutions and products, run on its Accelerator operating system and its Forge intelligence layer. It has more than 50,000 employees and decades of operating data from a global installed base. Its Building Automation business sells controls, sensors, fire and security systems for commercial buildings. Industrial Automation covers process control, sensing, warehouse automation and the productivity (barcode scanning) business, and the process-technology franchise licenses refining and petrochemical technology and supplies the equipment and services around it, such as its planned role at the Dangote refinery project in Kenya. Honeywell makes money from a mix of equipment sales, long-cycle projects, recurring service and growing software offerings.

Full HON guide

CC vs HON: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • CC drivers: Opteon refrigerant growth; TiO2 pigment cyclical recovery.
  • HON drivers: Pure-play automation focus; Software and physical AI on the installed base.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. For HON, as a standalone automation company, Honeywell is more exposed to construction activity, manufacturing capex and energy-sector spending than when aerospace aftermarket revenue cushioned results.

CC or HON: which should you pick?

If the story you believe is CC's (Opteon refrigerant growth), CC is the more direct way to own it; if it is HON's (Pure-play automation focus), HON is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CC and HON guides.

CC vs HON: the full fundamentals

CC. At about $11.27 a share on November 20, 2026, Chemours is valued at roughly $1.7 billion, or about 0.29 times its ~$5.84 billion revenue, a cyclical-and-litigation discount rather than a growth multiple. There is no trailing P/E because of GAAP losses, while the forward P/E of about 6.5 rests on analysts' 2027 EPS estimate of about $1.72 roughly doubling 2026's ~$0.81. EV/EBITDA near 10.6 shows how much of the enterprise value sits in about $3.9 billion of gross debt; consensus for the fourth quarter is EPS of about $0.14 on revenue of about $1.42 billion.

HON. Honeywell's headline numbers are still hard to read because the June 2026 aerospace spin-off and a large Q2 gain sit inside the trailing figures, which is why the trailing P/E shows near 11x. On forward estimates the stock trades around 22x 2027 EPS of about $9.88 and roughly 8.9x EV/EBITDA, a multiple in line with quality automation peers. The Q3 report gave the first clean standalone quarter, with a modest EPS beat and revenue in line.

Headline figures (approximate, November 2026): CC shows revenue (ttm) ~$5.84B, revenue growth (q3 2026, yoy) ~+3% (~$1.54B), net income (ttm) ~-$154M (Q3 2026 GAAP ~+$196M), q3 2026 adj. eps vs est. $0.21 vs $0.26; HON shows revenue (ttm, includes aerospace until june) ~$37.7 billion, q3 2026 revenue (continuing operations) ~$5.0 billion, up ~1.3% YoY, q3 2026 eps ~$2.27 vs ~$2.16 estimate; net income ~$664 million, 2026 revenue (analyst consensus) ~$20.2 billion; 2026 EPS ~$8.42, 2027 ~$9.88.

The bottom line: CC vs HON

CC and HON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CC and HON exposure against your real portfolio. It is not an investment adviser.

Wondering how CC or HON fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about The Chemours Company

Ask Walnut's AI anything about CC and see how it fits what you own.

FAQ

What is the difference between CC and HON?

+

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. Honeywell, which now operates as Honeywell Technologies (Nasdaq: HON), describes itself as a global, pure-play automation company serving the building, industrial and process sectors through services, solutions and products, run on its Accelerator operating system and its Forge intelligence layer. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CC or HON the better stock?

+

Neither is universally better. HON is the larger incumbent; CC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CC or HON?

+

On forward P/E (as of November 2026), CC trades at 6.53x and HON at 21.97x, so CC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CC and HON?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CC vs HON?

+

CC: PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition, although pigment pricing improved in the third quarter of 2026. The refrigerant business has its own cyclicality, with Opteon volumes down about 9 percent in that quarter. The company posted GAAP net losses in the three quarters before the third, including about $274 million in Q2 2026, and still has a trailing net loss of about $154 million. Gross debt of about $3.9 billion, net leverage near 4.3 times, and the cash demands of legal settlements constrain financial flexibility, and the dividend currently exceeds GAAP earnings. Regulatory, raw-material, and currency swings add further volatility to results. Walnut is not an investment adviser; this page describes the business and is not a recommendation. HON: As a standalone automation company, Honeywell is more exposed to construction activity, manufacturing capex and energy-sector spending than when aerospace aftermarket revenue cushioned results. Earnings are expected to fall sharply in reported terms in 2026 (consensus of about $8.42 of EPS versus far higher prior-year figures that included aerospace), and the separation adds execution risk: stranded costs, new capital structures and a limited standalone reporting history. Debt of about $17.2 billion against about $6.2 billion of cash as of September 2026 leaves the balance sheet a watch point, and Q3 revenue growth of ~1.3% shows how modest organic growth is for now. The productivity solutions (warehouse and barcode) business has shown cyclical softness, and analysts have been trimming price targets (Mizuho cut its target to $255 from $265 in October). Input costs, supply chains and currency swings also affect margins.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CC or HON; figures are approximate and dated (as of November 2026). Verify current data before investing.